Market Perception of Viking Therapeutics – A Comprehensive Analysis

Viking Therapeutics stock is trading -31.5% below its average target price of $113.91 after marking a 6.6% during today's morning session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $90.0 to $138.0 per share.

The stock has an unusually large proportion of its shares sold short at 17.3%, and a short ratio of 5.25. Since 6.0% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 74.9% of Viking Therapeutics's shares being owned by this investor type.

Institutions Invested in Viking Therapeutics

Date Reported Holder Percentage Shares Value
2024-06-30 FMR, LLC 15% 16,540,281 $1,290,638,106
2024-06-30 Vanguard Group Inc 9% 10,097,337 $787,895,193
2024-06-30 Blackrock Inc. 5% 6,026,131 $470,218,994
2024-06-30 State Street Corporation 5% 5,122,428 $399,703,050
2024-06-30 JP Morgan Chase & Company 2% 2,251,671 $175,697,885
2024-06-30 Geode Capital Management, LLC 2% 1,859,082 $145,064,166
2024-06-30 Susquehanna International Group, LLP 1% 1,404,715 $109,609,909
2024-06-30 Pictet Asset Management Holding SA 1% 1,381,374 $107,788,611
2024-06-30 Viking Global Investors, L.P. 1% 1,354,450 $105,687,731
2024-09-30 Perpetual Ltd. 1% 1,269,152 $99,031,929

Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Viking Therapeutics.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS